ESALY News and Press, Eisai Co. Ltd. ADR From 03/31/23

Eisai: Additional Detailed Analyses from Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals TOKYO and CAMBRIDGE, Mass., Mar 31, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that three additional detailed analy...

Eisai to Present Research from Oncology Portfolio at The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer TOKYO, Mar 24, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of two abstracts at the Society of Gynecologic Oncology (SGO) ...

Eisai to Present New Lecanemab Data, Including Research Evaluating Safety Profile, Clinical Outcomes and Quality of Life Measures, as Well as Other Important Alzheimer's Disease Research, at the AD/PD 2023 Annual Meeting TOKYO, Mar 23, 2023 - (JCN Newswire) - Eisai Co., Ltd. announc...

2023-03-16 08:45:38 ET Summary More than likely the Food and Drug Administration will grant full approval to Leqembi in July which should boost Biogen and Eisai's stock value. If the FDA grants full approval, Medicare has indicated that it will expand coverage for the drug. Bi...

U.S. Veterans' Health Administration (VHA) Provides Coverage of LEQEMBI (lecanemab-Irmb) Two Months After LEQEMBI's FDA Accelerated Approval for Veterans Living with Early Stages of Alzheimer's Disease TOKYO, Mar 14, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that the U...

Eisai Receives the "Basic Achievement Grand Prize" at the 2023 J-Win Diversity Award TOKYO, Mar 10, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that it was selected as the winner of the "Basic Achievement Grand Prize" at the "2023 J-Win Diversity Award" held by non-profi...

Eisai Certified as a 2023 Health and Productivity Management Outstanding TOKYO, Mar 9, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been certified as a Health and Productivity Management Outstanding Organization in the large enterprise category (White 500) by ...

FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer's Disease TOKYO and CAMBRIDGE, Mass., Mar 6, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen...

Biogen Japan and Eisai Provide Update on Co-Promotion Of Multiple Sclerosis Treatments In Japan TOKYO, Mar 2, 2023 - (JCN Newswire) - Biogen Japan Ltd. and Eisai Co., Ltd. announced today the termination of the co-promotion agreement that has been in place since January 2018 for Bio...

Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration TOKYO, Feb 28, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the Biologics License Application (BLA) for lecanemab (brand name ...